Glucagon Use in Colonoscopies
Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial
1 other identifier
interventional
100
1 country
1
Brief Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Apr 2014
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 24, 2014
CompletedFirst Posted
Study publicly available on registry
March 5, 2014
CompletedStudy Start
First participant enrolled
April 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2018
CompletedResults Posted
Study results publicly available
April 20, 2021
CompletedJuly 3, 2025
July 1, 2025
4.1 years
February 24, 2014
March 24, 2021
July 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adenoma Detection Rate (ADR) During Colonoscopy Procedure
ADR was defined as the percentage of participants with at least one traditional adenoma (including tubular or villous adenomas, and adenomas with high grade dysplasia or adenocarcinoma) of any size.
During colonoscopy procedure (an average of 1139 seconds for Glucagon Arm and 1353 seconds for Placebo Arm)
Study Arms (2)
Glucagon
ACTIVE COMPARATOR1 mg glucagon given during colonoscopy through an IV
Placebo
PLACEBO COMPARATOR1 mL normal saline given during colonoscopy through an IV
Interventions
Eligibility Criteria
You may qualify if:
- Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center.
You may not qualify if:
- Refusal to give informed consent.
- Age \<18 or \>70.
- Prior intra-abdominal surgery
- Diabetes
- Pheochromocytoma
- Insulinoma
- Liver disease (Child-Pugh Score \>6)
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
San Francisco General Hospital
San Francisco, California, 94117, United States
Related Publications (1)
Anupam Aditi, Trilokesh Dey Kidambi, Angel Espinoza, Nicholas Crowley, Alex Rodas, John Patrick Cello. Glucagon Shortens Cecal Intubation Time and Total Procedure Time During Colonoscopy: A Prospective, Double-Blind Placebo Controlled Randomized Trial. Biomedical Journal of Scientific & Technical Research. 2019; 22(2).
RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- John Cello, MD
- Organization
- University of California, San Francisco
Study Officials
- PRINCIPAL INVESTIGATOR
John Cello, MD
University of California, San Francisco
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 24, 2014
First Posted
March 5, 2014
Study Start
April 1, 2014
Primary Completion
May 1, 2018
Study Completion
May 1, 2018
Last Updated
July 3, 2025
Results First Posted
April 20, 2021
Record last verified: 2025-07